Osteonecrose da mandíbula relacionada a medicamentos (ONMRM)

Introduction: Medication-related osteonecrosis of the jaw, formerly known as bisphosphonate-associated osteonecrosis of the jaw, is a syndrome first described in 2003. Prescription drugs such as bisphosphonates, denosumab and anti-angiogenic agents, including monoclonal antibodies, have been implicated in the development of medication-related osteonecrosis of the jaw (MRONJ). Purpose: The aim of this research was to investigate drugs related to osteonecrosis of the jaw. Method: This were a quantitative, cross-sectional descriptive study, using a search of scientific databases to collect information on the drugs associated with the development of drug-related osteonecrosis of the jaw. Result: Bisphosphonates have been associated with the development of osteonecrosis of the jaw, as they inhibit osteoclastic activity by altering bone remodeling. Denosumab was introduced as a more effective alternative to bisphosphonates; however, it has also been linked to the production of osteonecrosis of the jaw, as this drug induces a sustained decrease in bone turnover. Conclusions: Osteonecrosis of the jaw has been linked to some drugs, which include bisphosphonates, especially zoledronic acid. Another drug that has been implicated in osteonecrosis of the jaw is denosumab, which is used for the treatment of osteoporosis and metastatic bone disease.